Get started

AIM ImmunoTech Inc

No trades
See on Supercharts
Overview
News Ideas Financials Technicals Forecast

AIM chart

Key stats

Market capitalization
24.282MUSD
Dividends yield (FY)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.4007USD

About AIM ImmunoTech Inc

Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Thomas Kenwood Equels
Website
aimimmuno.com
Headquarters
Ocala
Employees
24
Founded
1966
ISIN
US00901B1052

AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Ocala, FL.

Ideas

AIM 1W Final Edit Wave (4) (A)(B)(C) CorrectiveTest AIM ImmunoTech, Inc. operates as a biopharmaceutical company, which engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders. Its products include Alferon N Injection and Ampligen. The A
Long
AIM AIM post covid therapy treatment Big Market value potential About AIM ImmunoTech Inc. AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease cau
Long
AIM Aim Immuno - Top pick for at least 500% plus gain Based on recent data and the indications , safety data (already used in humans) and a need by various communities such as people afflicted with ME this should be the number one meme stock for getting people help while sticking it to the naked shorts. Insiders buying and with indications and data i
Long
AIM; Small Chart Analysis, Possible Cup and Handle formingDISCLAIMER This is in no way, shape or form, fluid and function, an analytical, qualitative or intelligent compte rendu. There is absolutely no financial advice here because the only financial advice I can give is to research, research, and research. The purpose of this analysis is to serve as an e
Long
AIM for the Sky*! Mileage may vary.Hello, take a seat and enjoy my basic analysis of AIM. I am not an analyst, of finances or anything else, just a dude saying friendly dude things. I could be the dude that everyone is friends with at the office, or I could be your crazy QAnon neighbour with a Ron Paul sign out front. Please do not t
Long
$AIM: Potential 35-55% upside from today's closesee easy and self explanatory boxes on chart for Entry, Exit and Stop loss zones. Never chase any stock. Not for any recommendation, Just an Idea. Like it >> Click 👍/comment, and follow. Last week closed 3 trades from previous posts ( HX +65% in 83 days; CYRN +29% in 36 days; SPCB +80 in 31 days)
Long
AIM: Greatest thing since sliced bread 🍞🔪Peaks are getting lower while troughs are getting higher in the duration of 5 days. You won't get a more obvious pennant than this. Now what makes this pennant bullish ? Well if we look at the Weekly log scale, we can see a clear case of a cup and handle, and we're almost done with the handle :)
Long
granted EU Orphan Drug Designation for RintatolimodJUST GOT POSITIVE EU RECOMMENDATION $AIM (old $HEB) granted EU Orphan Drug Designation for Rintatolimod for treatment of pancreatic cancer, Hemispherx Biopharma Europe. Rintatolimod is Ampligen This is going to trap shorts and when they PR this is going to explode! www.ema.europa.eu

See all ideas 

News Flow

Keep readingKeep reading

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating

An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Be warned
This info isn't a recommendation for what you should personally do, so please don't take the data as investment advice. As with any trade, always look first, then leap. Read more in the Terms of Use.

Financials

Performance
Revenue to profit conversion
Total revenue
Gross profit
EBITDA
EBIT
Net income
‪0%‬
‪0%‬
‪0%‬
‪0%‬
‪0%‬
Debt level and coverage
Earnings
Next:—
‪0‬

Trading & brokers

TradeStation
TradeStation
Featured
Stocks, Crypto, Futures
4.43Fabulous
Learn more
OANDA
OANDA
Forex
4.52Great
Learn more
Interactive Brokers
Interactive Brokers
Stocks, Futures, Bonds
4.36Fabulous
Learn more
FOREX.com
FOREX.com
Forex
4.35Fabulous
Learn more

See all brokers 

Gain new superpowers

Take your analysis to the next level with our full suite of features, known and used by millions throughout the trading world.Learn more